Adjuvant Endocrine Therapy
Adjuvant endocrine therapy is a mainstay of treatment for women with hormone-receptor (estrogen-receptor and/or progesterone-receptor) expressing breast cancers. Extensive clinical trials over decades have demonstrated compelling improvements in overall survival and disease-free survival with use of adjuvant endocrine therapy. Along with implementation of widespread screening mammography programs, use of adjuvant endocrine therapy has contributed substantially to the decline in breast cancer mortality seen in the US and other developed societies. Around the world, it is likely that adjuvant endocrine treatment has contributed more to the reduction in cancer mortality than any other therapy employed in medical oncology. This chapter provides an overview of current adjuvant endocrine approaches to breast cancer therapy.
KeywordsBreast Cancer Premenopausal Woman Aromatase Inhibitor Adjuvant Endocrine Therapy Tamoxifen Treatment
- 3.Peto R, Davies C; on Behalf of the ATLAS Collaboration. ATLAS (adjuvant tamoxifen, longer against shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 2010,500 women preliminary results. In: 30th Annual San Antonio Breast Cancer Symposium; 2007:abstract 48. Available at www.sabcs.org.
- 4.Gray RG, Rea DW, Handley K, Marshall A, Pritchard G, Perry P, et al. aTTom (adjuvant Tamoxifen–To offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer–preliminary results. Proc ASCO; 2008:abstract 513. Available at: www.asco.org.
- 5.Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N, Merajver S, Romond EH, Kardinal CG, Shibata HR, Margolese RG, Farrar WB. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 2001;19(4):931–42.Google Scholar
- 8.Albain K, Barlow W, Shak S, Hortobagyi G, Livingston R, Yeh I, Ravdin P, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ET-positive breast cancer. in: 27th Annual San Antonio Breast Cancer Supplement Symposium; 2004:abstract 37. Breast Cancer Research and Treatment 2007; S8814,INT0100.Google Scholar
- 9.Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 1996;14(10):2731–7.PubMedGoogle Scholar
- 18.Anon. Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1996;348(9036):201089–96.Google Scholar
- 19.International Breast Cancer Study Group (IBCSG), Castiglione-Gertsch M, O’Neill A, Price KN, Goldhirsch A, Coates AS, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst. 2003;95(24):1833–46.Google Scholar
- 20.LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, Sainsbury R. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369(9574):172010–23.Google Scholar
- 23.International Breast Cancer Study Group, Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol. 2006;24(9):1332–41.Google Scholar
- 26.Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Poestlberger S, Menzel C, et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive stage I and II breast cancer : First efficacy results from ABCSG-12. J Clin Oncol 2008;26(suppl):abstract LBA4.Google Scholar
- 31.Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006;24:3629–35.PubMedCrossRefGoogle Scholar
- 32.Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007;8:20109–27.CrossRefGoogle Scholar
- 37.Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell’Orto P, Rasmussen BB, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007;25(25):3846–52.PubMedCrossRefGoogle Scholar
- 38.Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell’Orto P, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008;26:5569–75.PubMedCrossRefGoogle Scholar
- 41.BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, et al (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361:766–776.Google Scholar
- 42.Rea D, Hasenburg A, Seynaeve C, et al. Presented at the 32nd Annual San Antonio Breast Cancer Symposium (December 9-13, 2009, San Antonio, TX), Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: The TEAM Trial, a prospective, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancer).Google Scholar